{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T13:41:43Z","timestamp":1791380503330,"version":"4.3.3"},"reference-count":64,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2018,1,1]],"date-time":"2018-01-01T00:00:00Z","timestamp":1514764800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,1,1]],"date-time":"2019-01-01T00:00:00Z","timestamp":1546300800000},"content-version":"vor","delay-in-days":365,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","heartfailure.onlinejacc.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["JACC: Heart Failure"],"published-print":{"date-parts":[[2018,1]]},"DOI":"10.1016\/j.jchf.2017.07.012","type":"journal-article","created":{"date-parts":[[2017,12,25]],"date-time":"2017-12-25T19:06:42Z","timestamp":1514228802000},"page":"1-7","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":103,"title":["Distinct Myocardial Targets for Diabetes\u00a0Therapy in Heart Failure With Preserved or\u00a0Reduced Ejection Fraction"],"prefix":"10.1016","volume":"6","author":[{"given":"Walter J.","family":"Paulus","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elisa","family":"Dal Canto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jchf.2017.07.012_bib1","doi-asserted-by":"crossref","first-page":"2281","DOI":"10.1016\/j.jacc.2014.08.036","article-title":"Noncardiac comorbidities in heart failure with reduced versus preserved ejection fraction","volume":"64","author":"Mentz","year":"2014","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.jchf.2017.07.012_bib2","doi-asserted-by":"crossref","first-page":"998","DOI":"10.1016\/j.jacc.2011.11.040","article-title":"Impact of noncardiac comorbidities on morbidity and mortality in a predominantly male population with heart failure and preserved versus reduced ejection fraction","volume":"59","author":"Ather","year":"2012","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.jchf.2017.07.012_bib3","doi-asserted-by":"crossref","first-page":"1377","DOI":"10.1093\/eurheartj\/ehn153","article-title":"Impact of diabetes on outcomes in patients with low and preserved ejection fraction heart failure: an analysis of the Candesartan in Heart failure: Assessment of Reduction in Mortality and morbidity (CHARM) programme","volume":"29","author":"MacDonald","year":"2008","journal-title":"Eur Heart J"},{"key":"10.1016\/j.jchf.2017.07.012_bib4","doi-asserted-by":"crossref","first-page":"324","DOI":"10.1161\/CIRCHEARTFAILURE.110.959890","article-title":"Body mass index and adverse cardiovascular outcomes in heart failure patients with preserved ejection fraction\/clinical perspective","volume":"4","author":"Haass","year":"2011","journal-title":"Circ Heart Fail"},{"key":"10.1016\/j.jchf.2017.07.012_bib5","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1161\/CIRCULATIONAHA.107.728550","article-title":"Diastolic stiffness of the failing diabetic heart: importance of fibrosis, advanced glycation end products, and myocyte resting tension","volume":"117","author":"van Heerebeek","year":"2008","journal-title":"Circulation"},{"key":"10.1016\/j.jchf.2017.07.012_bib6","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1016\/j.jacc.2013.02.092","article-title":"A\u00a0novel paradigm for heart\u00a0failure with preserved ejection fraction: comorbidities drive myocardial dysfunction and remodeling through coronary microvascular endothelial inflammation","volume":"62","author":"Paulus","year":"2013","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.jchf.2017.07.012_bib7","doi-asserted-by":"crossref","first-page":"1868","DOI":"10.1056\/NEJMcp1511175","article-title":"Heart Failure with Preserved Ejection Fraction","volume":"375","author":"Redfield","year":"2016","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jchf.2017.07.012_bib8","doi-asserted-by":"crossref","first-page":"1338","DOI":"10.1093\/eurjhf\/hfs130","article-title":"Growth differentiation factor 15, ST2, high-sensitivity troponin T, and N-terminal pro brain natriuretic peptide in heart failure with preserved vs. reduced ejection fraction","volume":"14","author":"Santhanakrishnan","year":"2012","journal-title":"Eur J Heart Fail"},{"key":"10.1016\/j.jchf.2017.07.012_bib9","doi-asserted-by":"crossref","first-page":"1006","DOI":"10.1002\/ejhf.414","article-title":"Circulating biomarkers of distinct pathophysiological pathways in heart failure with preserved vs. reduced left ventricular ejection fraction","volume":"17","author":"Sanders-van Wijk","year":"2015","journal-title":"Eur J Heart Fail"},{"key":"10.1016\/j.jchf.2017.07.012_bib10","first-page":"312","article-title":"Myocardial microvascular inflammatory endothelial activation in heart failure with preserved ejection fraction","volume":"4","author":"Franssen","year":"2016","journal-title":"J\u00a0Am Coll Cardiol HF"},{"issue":"Suppl 5","key":"10.1016\/j.jchf.2017.07.012_bib11","doi-asserted-by":"crossref","first-page":"S35","DOI":"10.1016\/j.jacc.2008.09.055","article-title":"The pathologic continuum of diabetic vascular disease","volume":"53","author":"Orasanu","year":"2009","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.jchf.2017.07.012_bib12","doi-asserted-by":"crossref","first-page":"550","DOI":"10.1161\/CIRCULATIONAHA.114.009625","article-title":"Coronary microvascular rarefaction and myocardial fibrosis in heart failure with preserved ejection fraction","volume":"131","author":"Mohammed","year":"2015","journal-title":"Circulation"},{"key":"10.1016\/j.jchf.2017.07.012_bib13","doi-asserted-by":"crossref","first-page":"e002562","DOI":"10.1161\/CIRCHEARTFAILURE.115.002562","article-title":"Reduced myocardial flow in heart failure patients with preserved ejection fraction","volume":"9","author":"Srivaratharajah","year":"2016","journal-title":"Circ Heart Fail"},{"key":"10.1016\/j.jchf.2017.07.012_bib14","doi-asserted-by":"crossref","first-page":"845","DOI":"10.1016\/j.jacc.2010.03.077","article-title":"Global cardiovascular reserve dysfunction in heart failure with preserved ejection fraction","volume":"56","author":"Borlaug","year":"2010","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.jchf.2017.07.012_bib15","doi-asserted-by":"crossref","first-page":"1778","DOI":"10.1016\/j.jacc.2012.07.036","article-title":"Incremental prognostic significance of peripheral endothelial dysfunction in patients with heart failure with normal left ventricular ejection fraction","volume":"60","author":"Akiyama","year":"2012","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.jchf.2017.07.012_bib16","first-page":"4","article-title":"Abnormal remodeling of subcutaneous small arteries is associated with early diastolic impairment in metabolic syndrome","volume":"6","author":"Khavandi","year":"2017","journal-title":"J\u00a0Am Heart Assoc"},{"key":"10.1016\/j.jchf.2017.07.012_bib17","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1161\/CIRCHEARTFAILURE.109.931451","article-title":"Cardiac inflammation contributes to changes in the extracellular matrix in patients with heart failure and normal ejection fraction","volume":"4","author":"Westermann","year":"2011","journal-title":"Circ Heart Fail"},{"key":"10.1016\/j.jchf.2017.07.012_bib18","doi-asserted-by":"crossref","first-page":"2164","DOI":"10.1016\/S0735-1097(03)00471-6","article-title":"Increased myocardial NADPH oxidase activity in human heart failure","volume":"41","author":"Heymes","year":"2003","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.jchf.2017.07.012_bib19","doi-asserted-by":"crossref","first-page":"1855","DOI":"10.1016\/j.amjcard.2016.08.077","article-title":"Effect of heart failure with preserved ejection fraction on nitric oxide metabolites","volume":"118","author":"Zamani","year":"2016","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.jchf.2017.07.012_bib20","doi-asserted-by":"crossref","first-page":"e004133","DOI":"10.1161\/JAHA.116.004133","article-title":"Heart failure, left ventricular remodeling, and circulating nitric oxide metabolites","volume":"5","author":"Chirinos","year":"2016","journal-title":"J\u00a0Am Heart Assoc"},{"key":"10.1016\/j.jchf.2017.07.012_bib21","doi-asserted-by":"crossref","first-page":"830","DOI":"10.1161\/CIRCULATIONAHA.111.076075","article-title":"Low myocardial protein kinase g activity in heart failure with preserved ejection fraction","volume":"126","author":"Van Heerebeek","year":"2012","journal-title":"Circulation"},{"key":"10.1016\/j.jchf.2017.07.012_bib22","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1016\/j.jacc.2005.09.050","article-title":"The pathogenesis of myocardial fibrosis in the setting of diabetic cardiomyopathy","volume":"47","author":"Asburn","year":"2006","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.jchf.2017.07.012_bib23","doi-asserted-by":"crossref","first-page":"e000433","DOI":"10.1161\/JAHA.113.000433","article-title":"Taking diabetes to heart: deregulation of myocardial lipid metabolism in diabetic cardiomyopathy","volume":"2","author":"Bayeva","year":"2013","journal-title":"J\u00a0Am Heart Assoc"},{"key":"10.1016\/j.jchf.2017.07.012_bib24","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1002\/(SICI)1099-0895(199812)14:4<263::AID-DMR233>3.0.CO;2-C","article-title":"Regulatory interactions between lipids and carbohydrates: the glucose fatty acid cycle after 35 years","volume":"14","author":"Randle","year":"1998","journal-title":"Diabetes Metab Rev"},{"key":"10.1016\/j.jchf.2017.07.012_bib25","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1152\/physrev.00025.2005","article-title":"Transcriptional regulation of metabolism","volume":"86","author":"Desvergne","year":"2006","journal-title":"Physiol Rev"},{"key":"10.1016\/j.jchf.2017.07.012_bib26","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1152\/physrev.00015.2009","article-title":"Myocardial fatty acid metabolism in health and disease","volume":"90","author":"Lopaschuk","year":"2010","journal-title":"Physiol Rev"},{"key":"10.1016\/j.jchf.2017.07.012_bib27","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1016\/j.jacc.2007.10.021","article-title":"Insulin-resistant cardiomyopathy: clinical evidence, mechanisms, and treatment options","volume":"51","author":"Witteles","year":"2008","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.jchf.2017.07.012_bib28","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1152\/physiol.00008.2006","article-title":"Mitochondrial uncoupling: a key contributor to reduced cardiac efficiency in diabetes","volume":"21","author":"Boudina","year":"2006","journal-title":"Physiology"},{"key":"10.1016\/j.jchf.2017.07.012_bib29","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1016\/S0735-1097(03)00625-9","article-title":"Diastolic dysfunction is associated with altered myocardial metabolism in asymptomatic normotensive patients with well-controlled type 2 diabetes mellitus","volume":"42","author":"Diamant","year":"2003","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.jchf.2017.07.012_bib30","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1097\/HJH.0b013e328013e7dd","article-title":"Advanced glycation endproduct crosslink breaker (alagebrium) improves endothelial function in patients with isolated systolic hypertension","volume":"25","author":"Zieman","year":"2007","journal-title":"J\u00a0Hypertens"},{"key":"10.1016\/j.jchf.2017.07.012_bib31","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1007\/s00418-010-0706-x","article-title":"Combined immunoelectron microscopic and computer\u2013assisted image analyses to detect advanced glycation end-products in human myocardium","volume":"134","author":"Donaldson","year":"2010","journal-title":"Histochem Cell Biol"},{"key":"10.1016\/j.jchf.2017.07.012_bib32","doi-asserted-by":"crossref","first-page":"1235","DOI":"10.1161\/CIRCULATIONAHA.105.581397","article-title":"Glycated proteins stimulate reactive oxygen species production in cardiac myocytes: involvement of Nox2 (gp91phox)-containing NADPH oxidase","volume":"113","author":"Zhang","year":"2006","journal-title":"Circulation"},{"key":"10.1016\/j.jchf.2017.07.012_bib33","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1016\/j.ejphar.2016.07.008","article-title":"Blockade of receptor for advanced glycation end products protects against systolic overload-induced heart failure after transverse aortic constriction in mice","volume":"791","author":"Liu","year":"2016","journal-title":"Eur J Pharmacol"},{"key":"10.1016\/j.jchf.2017.07.012_bib34","doi-asserted-by":"crossref","first-page":"11794","DOI":"10.1073\/pnas.1116584109","article-title":"Cardiomyocyte-specific I\u03baB kinase (IKK)\/NF-\u03baB activation induces reversible inflammatory cardiomyopathy and heart failure","volume":"109","author":"Maier","year":"2012","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.jchf.2017.07.012_bib35","doi-asserted-by":"crossref","first-page":"1718","DOI":"10.1093\/eurheartj\/ehv134","article-title":"Clinical diabetic cardiomyopathy: a two-faced disease with restrictive and dilated phenotypes","volume":"36","author":"Seferovi\u0107","year":"2015","journal-title":"Eur Heart J"},{"key":"10.1016\/j.jchf.2017.07.012_bib36","doi-asserted-by":"crossref","first-page":"2791","DOI":"10.2337\/diacare.26.10.2791","article-title":"Diabetes and idiopathic cardiomyopathy: a nationwide case-control study","volume":"26","author":"Bertoni","year":"2003","journal-title":"Diabetes Care"},{"key":"10.1016\/j.jchf.2017.07.012_bib37","doi-asserted-by":"crossref","first-page":"1224","DOI":"10.1093\/eurheartj\/ehn156","article-title":"Diabetes, left ventricular systolic dysfunction, and chronic heart failure","volume":"29","author":"MacDonald","year":"2008","journal-title":"Eur Heart J"},{"key":"10.1016\/j.jchf.2017.07.012_bib38","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1007\/s11154-012-9235-3","article-title":"Lipotoxicity contributes to endothelial dysfunction: a focus on the contribution from ceramide","volume":"14","author":"Symons","year":"2013","journal-title":"Rev Endocr Metab Disord"},{"key":"10.1016\/j.jchf.2017.07.012_bib39","doi-asserted-by":"crossref","first-page":"1048","DOI":"10.1161\/CIRCIMAGING.113.000565","article-title":"Effects of age and aerobic fitness on myocardial lipid content","volume":"6","author":"Sarma","year":"2013","journal-title":"Circ Cardiovasc Imaging"},{"key":"10.1016\/j.jchf.2017.07.012_bib40","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1016\/j.jacc.2014.05.030","article-title":"Cardiovascular phenotype in HFpEF patients with or without diabetes: a RELAX trial ancillary study","volume":"64","author":"Lindman","year":"2014","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.jchf.2017.07.012_bib41","doi-asserted-by":"crossref","first-page":"724","DOI":"10.1161\/CIRCULATIONAHA.116.024593","volume":"135","author":"Kristensen","year":"2017","journal-title":"Circulation"},{"key":"10.1016\/j.jchf.2017.07.012_bib42","doi-asserted-by":"crossref","first-page":"710","DOI":"10.1161\/CIRCHEARTFAILURE.112.968594","article-title":"Comorbidity and ventricular and vascular structure and function in heart failure with preserved ejection fraction: a community based study","volume":"5","author":"Mohammed","year":"2012","journal-title":"Circ Heart Fail"},{"key":"10.1016\/j.jchf.2017.07.012_bib43","doi-asserted-by":"crossref","first-page":"725","DOI":"10.1002\/ejhf.288","article-title":"Clinical characteristics and outcomes of patients with and without diabetes in the Surgical Treatment for Ischemic Heart Failure (STICH) trial","volume":"17","author":"MacDonald","year":"2015","journal-title":"Eur J Heart Fail"},{"key":"10.1016\/j.jchf.2017.07.012_bib44","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1093\/eurjhf\/hfr125","article-title":"Left ventricular systolic and diastolic function, remodelling, and clinical outcomes among patients with diabetes following myocardial infarction and the influence of direct renin inhibition with aliskiren","volume":"14","author":"Shah","year":"2012","journal-title":"Eur J Heart Fail"},{"key":"10.1016\/j.jchf.2017.07.012_bib45","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1093\/ehjci\/jes165","article-title":"Abnormal glucose metabolism is associated with reduced left ventricular contractile reserve and exercise intolerance in patients with chronic heart failure","volume":"14","author":"Egstrup","year":"2013","journal-title":"Eur Heart J Cardiovasc Imaging"},{"key":"10.1016\/j.jchf.2017.07.012_bib46","doi-asserted-by":"crossref","first-page":"985","DOI":"10.2337\/dc12-1116","article-title":"Influence of diabetes on left ventricular systolic and diastolic function and on long-term outcome after cardiac resynchronization therapy","volume":"36","author":"H\u00f6ke","year":"2013","journal-title":"Diabetes Care"},{"key":"10.1016\/j.jchf.2017.07.012_bib47","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1093\/eurjhf\/hfn018","article-title":"A\u00a0randomized trial of the impact of strict glycaemic control on myocardial diastolic function and perfusion reserve: a report from the DADD (Diabetes mellitus And Diastolic Dysfunction) study","volume":"11","author":"Jarnert","year":"2009","journal-title":"Eur J Heart Fail"},{"key":"10.1016\/j.jchf.2017.07.012_bib48","doi-asserted-by":"crossref","first-page":"938","DOI":"10.1016\/j.ahj.2011.07.030","article-title":"Intensive glycemic control has no impact on the risk of heart failure in type 2 diabetic patients: evidence from a 37,229 patient meta-analysis","volume":"162","author":"Castagno","year":"2011","journal-title":"Am Heart J"},{"key":"10.1016\/j.jchf.2017.07.012_bib49","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1093\/eurjhf\/hfn033","article-title":"The dialogue between diabetes and diastole","volume":"11","author":"van Heerebeek","year":"2009","journal-title":"Eur J Heart Fail"},{"key":"10.1016\/j.jchf.2017.07.012_bib50","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1001\/jama.2015.17346","article-title":"Effect of caloric restriction or aerobic exercise training on peak oxygen consumption and quality of life in obese older patients with heart failure with preserved ejection fraction: a randomized clinical trial","volume":"315","author":"Kitzman","year":"2016","journal-title":"JAMA"},{"key":"10.1016\/j.jchf.2017.07.012_bib51","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1530\/EJE-10-0624","article-title":"Metformin is associated with improved left ventricular diastolic function measured by tissue Doppler imaging in patients with diabetes","volume":"163","author":"Andersson","year":"2010","journal-title":"Eur J Endocrinol"},{"key":"10.1016\/j.jchf.2017.07.012_bib52","doi-asserted-by":"crossref","first-page":"1526","DOI":"10.1001\/jama.2014.3315","article-title":"Effect of metformin on left ventricular function after acute myocardial infarction in patients without diabetes: the GIPS-III randomized clinical trial","volume":"311","author":"Lexis","year":"2014","journal-title":"JAMA"},{"key":"10.1016\/j.jchf.2017.07.012_bib53","doi-asserted-by":"crossref","first-page":"1129","DOI":"10.1016\/S0140-6736(07)61514-1","article-title":"Congestive heart failure and cardiovascular death in patients with prediabetes and type 2 diabetes given thiazolidinediones: a meta-analysis of randomised clinical trials","volume":"370","author":"Lago","year":"2007","journal-title":"Lancet"},{"key":"10.1016\/j.jchf.2017.07.012_bib54","doi-asserted-by":"crossref","first-page":"2069","DOI":"10.1161\/CIRCULATIONAHA.108.803916","article-title":"Pioglitazone improves cardiac function and alters myocardial substrate metabolism without affecting cardiac triglyceride accumulation and high-energy phosphate metabolism in patients with well-controlled type 2 diabetes mellitus","volume":"119","author":"van der Meer","year":"2009","journal-title":"Circulation"},{"key":"10.1016\/j.jchf.2017.07.012_bib55","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1186\/1475-2840-10-67","article-title":"Association of plasma osteoprotegerin and adiponectin with arterial function, cardiac function and metabolism in asymptomatic type 2 diabetic men","volume":"10","author":"Chen","year":"2011","journal-title":"Cardiovasc Diabetol"},{"key":"10.1016\/j.jchf.2017.07.012_bib56","doi-asserted-by":"crossref","first-page":"1579","DOI":"10.1161\/CIRCULATIONAHA.114.010389","article-title":"Heart failure, saxagliptin, and diabetes mellitus: observations from the SAVOR-TIMI 53 randomized trial","volume":"130","author":"Scirica","year":"2014","journal-title":"Circulation"},{"key":"10.1016\/j.jchf.2017.07.012_bib57","first-page":"573","article-title":"Sitagliptin use in patients with diabetes and heart failure: a population-based retrospective cohort study","volume":"2","author":"Weir","year":"2014","journal-title":"J\u00a0Am Coll Cardiol HF"},{"key":"10.1016\/j.jchf.2017.07.012_bib58","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1001\/jamacardio.2016.0184","article-title":"The safety of dipeptidyl peptidase 4 inhibitors and the risk for heart failure","volume":"1","author":"Scirica","year":"2016","journal-title":"JAMA Cardiol"},{"key":"10.1016\/j.jchf.2017.07.012_bib59","doi-asserted-by":"crossref","first-page":"i610","DOI":"10.1136\/bmj.i610","article-title":"Dipeptidyl peptidase-4 inhibitors and risk of heart failure in type 2 diabetes: systematic review and meta-analysis of randomised and observational studies","volume":"352","author":"Li","year":"2016","journal-title":"BMJ"},{"key":"10.1016\/j.jchf.2017.07.012_bib60","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1002\/ejhf.707","article-title":"Liraglutide in heart failure: caution is needed","volume":"19","author":"Komajda","year":"2017","journal-title":"Eur J Heart Fail"},{"key":"10.1016\/j.jchf.2017.07.012_bib61","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1002\/ejhf.657","article-title":"Effect of liraglutide, a glucagon-like peptide-1 analogue, on left ventricular function in stable chronic heart failure patients with and without diabetes (LIVE)-a multicentre, double-blind, randomised, placebo-controlled trial","volume":"19","author":"Jorsal","year":"2017","journal-title":"Eur J Heart Fail"},{"key":"10.1016\/j.jchf.2017.07.012_bib62","doi-asserted-by":"crossref","first-page":"1526","DOI":"10.1093\/eurheartj\/ehv728","article-title":"Heart failure outcomes with empagliflozin in patients with type 2 diabetes at high cardiovascular risk: results of the EMPA-REG OUTCOME trial","volume":"37","author":"Fitchett","year":"2016","journal-title":"Eur Heart J"},{"key":"10.1016\/j.jchf.2017.07.012_bib63","doi-asserted-by":"crossref","first-page":"644","DOI":"10.1056\/NEJMoa1611925","article-title":"Canagliflozin and cardiovascular and renal events\u00a0in type 2 diabetes","volume":"377","author":"Neal","year":"2017","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jchf.2017.07.012_bib64","doi-asserted-by":"crossref","first-page":"2646","DOI":"10.1016\/j.jacc.2017.04.014","article-title":"Novel diabetes drugs and the cardiovascular specialist","volume":"69","author":"Sattar","year":"2017","journal-title":"J\u00a0Am Coll Cardiol"}],"container-title":["JACC: Heart Failure"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2213177917305334?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2213177917305334?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2022,8,11]],"date-time":"2022-08-11T06:01:11Z","timestamp":1660197671000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2213177917305334"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,1]]},"references-count":64,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2018,1]]}},"alternative-id":["S2213177917305334"],"URL":"https:\/\/doi.org\/10.1016\/j.jchf.2017.07.012","relation":{},"ISSN":["2213-1779"],"issn-type":[{"value":"2213-1779","type":"print"}],"subject":[],"published":{"date-parts":[[2018,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Distinct Myocardial Targets for Diabetes\u00a0Therapy in Heart Failure With Preserved or\u00a0Reduced Ejection Fraction","name":"articletitle","label":"Article Title"},{"value":"JACC: Heart Failure","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jchf.2017.07.012","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 by the American College of Cardiology Foundation. Published by Elsevier.","name":"copyright","label":"Copyright"}]}}